Short answer: Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) look kidney-safe, and neither is cleared by the kidneys, so neither needs a dose change for reduced kidney function. The strongest hard-outcome kidney evidence today is for semaglutide (the FLOW trial). Tirzepatide produces greater weight loss and strong signals on albuminuria, but its dedicated kidney-outcome evidence is younger. “Safer” depends on your goal — there is no single winner for everyone.
What the kidney evidence actually shows. For semaglutide, the FLOW trial (people with type 2 diabetes and CKD) found it reduced major kidney events, with about a 24% lower risk of the primary outcome versus placebo — the clearest kidney-protection result in this drug class so far. For tirzepatide, SURPASS‑4 showed markedly less growth in albuminuria (protein leak) than insulin, and the newer SURPASS‑CVOT trial reported a 23% lower combined kidney endpoint — but that was against an active comparator (dulaglutide, itself a GLP‑1 drug), not placebo, so it is read as “at least as good” rather than a placebo-beating result.
Weight and metabolic effect. Head-to-head (SURMOUNT and SURPASS programs), tirzepatide generally produces more weight loss than semaglutide. Since obesity itself drives a specific kidney injury (obesity-related glomerulopathy), greater weight loss may carry its own long-term kidney benefit — but that is inferred, not yet proven as a hard kidney outcome.
Kidney handling and dosing. Neither drug is eliminated by the kidney, and neither label requires a dose adjustment for renal impairment. For both, the practical kidney risk is the same and indirect: nausea, vomiting, or diarrhea → dehydration → a temporary drop in eGFR, most likely alongside diuretics, ACE inhibitors/ARBs, SGLT2 inhibitors, or NSAIDs.
How clinicians often choose:
- Diabetic kidney disease, want proven kidney protection: semaglutide has the strongest dedicated outcome data (FLOW).
- Priority is maximum weight loss: tirzepatide usually wins on the scale, with reassuring albuminuria data.
- Tolerability: both cause GI side effects; the one you tolerate is the one that protects you, because it is the one you keep taking and stay hydrated on.
- Access and cost often decide the real-world choice.
Bottom line. For dedicated, hard-outcome kidney protection, semaglutide currently has the deeper evidence base. Tirzepatide offers greater weight loss and strong, if younger, kidney signals. Both are used safely across CKD stages without a dose change — the deciding factors are usually your primary goal, tolerability, and access.
Full guides: Semaglutide (Ozempic/Wegovy) and Your Kidneys and Tirzepatide (Mounjaro/Zepbound) and Your Kidneys.
Related questions
Is Ozempic or Mounjaro better for the kidneys? For proven, hard-outcome kidney protection in diabetic kidney disease, semaglutide has the strongest evidence (the FLOW trial, ~24% risk reduction). Tirzepatide shows strong albuminuria and kidney signals and more weight loss, but its dedicated kidney-outcome data are newer and compared against an active drug, not placebo.
Does either drug need a lower dose if I have kidney disease? No. Neither semaglutide nor tirzepatide is cleared by the kidneys, and neither label requires a dose adjustment for reduced kidney function. Both still need slow titration and attention to hydration.
Which one has fewer kidney side effects? Their kidney risk profile is similar and indirect: dehydration from GI side effects is the main concern for both. The better choice is often the one you tolerate, because staying on it and staying hydrated is what protects the kidney.
📬 Get two free guides + stay current. Join the newsletter and instantly get our two free PDF guides — Sick-Day Rules for Weight-Loss Injections and 5 Questions to Ask Before Starting a Weight-Loss Injection — plus a short monthly email when a new study actually changes how we think about weight-loss medication and your kidneys. No hype, no selling.
Written and medically reviewed by Dr. Amir S. Naderi, MD, FASN. Last updated: July 9, 2026. Educational information only — not medical advice. Never change or stop a prescribed medication without talking to your doctor.